Pfizer Inc and BioNTech SE announced on Wednesday that the first participants have been dosed in the US in the Phase 1/2 clinical trial for the BNT162 vaccine programme to prevent COVID-19.
Trending
- Fidelity Bank distributes food packs to FCT communities
- Ohanaeze youths rejects Reno Omokri’s ambassadorial nomination
- Presidency denies sacking INEC boss, Yakubu
- Pa Senbanjo for burial as Abiodun, Dangote, Otedola, others condole with family
- Falana urges FG to end killings, insecurity across states
- Police detain man for alleged daughter’s murder
- Wife tells court to further remand husband
- First Lady donates N1b to fight cervical cancer
